|
1
|
Dimopoulos MA and Terpos E: Multiple
myeloma. Ann Oncol. 21 Suppl 7:vii143–vii150. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Quach H, Prince HM and Spencer A: Managing
multiple myeloma in the elderly: Are we making progress? Expert Rev
Hematol. 4:301–315. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mateos MV, Masszi T, Grzasko N, Hansson M,
Sandhu I, Pour L, Viterbo L, Jackson SR, Stoppa AM, Gimsing P, et
al: Impact of prior therapy on the efficacy and safety of oral
ixazomib-lenalidomide-dexamethasone vs.
placebo-lenalidomide-dexamethasone in patients with
relapsed/refractory multiple myeloma in TOURMALINE-MM1.
Haematologica. 102:1767–1775. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moreau P, Masszi T, Grzasko N, Bahlis NJ,
Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, et al:
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple
Myeloma. N Engl J Med. 374:1621–1634. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Howells LM, Mitra A and Manson MM:
Comparison of oxaliplatin- and curcumin-mediated antiproliferative
effects in colorectal cell lines. Int J Cancer. 121:175–183. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jin G, Yang Y, Liu K, Zhao J, Chen X, Liu
H, Bai R, Li X, Jiang Y, Zhang X, et al: Combination curcumin and
(−)-epigallocatechin-3-gallate inhibits colorectal carcinoma
microenvironment-induced angiogenesis by JAK/STAT3/IL-8 pathway.
Oncogenesis. 6:e3842017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Weissenberger J, Priester M, Bernreuther
C, Rakel S, Glatzel M, Seifert V and Kögel D: Dietary curcumin
attenuates glioma growth in a syngeneic mouse model by inhibition
of the JAK1,2/STAT3 signaling pathway. Clin Cancer Res.
16:5781–5795. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zanotto-Filho A, Braganhol E, Klafke K,
Figueiró F, Terra SR, Paludo FJ, Morrone M, Bristot IJ, Battastini
AM, Forcelini CM, et al: Autophagy inhibition improves the efficacy
of curcumin/temozolomide combination therapy in glioblastomas.
Cancer Lett. 358:220–231. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ye M and Zhang J and Zhang J, Miao Q, Yao
L and Zhang J: Curcumin promotes apoptosis by activating the
p53-miR-192-5p/215-XIAP pathway in non-small cell lung cancer.
Cancer Lett. 357:196–205. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Srivastava RK, Chen Q, Siddiqui I, Sarva K
and Shankar S: Linkage of curcumin-induced cell cycle arrest and
apoptosis by cyclin-dependent kinase inhibitor p21(/WAF1/CIP1).
Cell Cycle. 6:2953–2961. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shinojima N, Yokoyama T, Kondo Y and Kondo
S: Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in
curcumin-induced autophagy. Autophagy. 3:635–637. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cao P, Maira SM, García-Echeverría C and
Hedley DW: Activity of a novel, dual PI3-kinase/mTor inhibitor
NVP-BEZ235 against primary human pancreatic cancers grown as
orthotopic xenografts. Br J Cancer. 100:1267–1276. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nassim R, Mansure JJ, Chevalier S, Cury F
and Kassouf W: Combining mTOR inhibition with radiation improves
antitumor activity in bladder cancer cells in vitro and in vivo: A
novel strategy for treatment. PLoS One. 8:e652572013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tasian SK, Teachey DT, Li Y, Shen F,
Harvey RC, Chen IM, Ryan T, Vincent TL, Willman CL, Perl AE, et al:
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in
murine xenograft models of Ph-like acute lymphoblastic leukemia.
Blood. 129:177–187. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zoncu R, Efeyan A and Sabatini DM: mTOR:
From growth signal integration to cancer, diabetes and ageing. Nat
Rev Mol Cell Biol. 12:21–35. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Suangtamai T and Tanyong DI: Diallyl
disulfide induces apoptosis and autophagy via mTOR pathway in
myeloid leukemic cell line. Tumour Biol. 37:10993–10999. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang FM, Galson DL, Roodman GD and Ouyang
H: Resveratrol triggers the pro-apoptotic endoplasmic reticulum
stress response and represses pro-survival XBP1 signaling in human
multiple myeloma cells. Exp Hematol. 39:999–1006. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Balasubramanyam K, Varier RA, Altaf M,
Swaminathan V, Siddappa NB, Ranga U and Kundu TK: Curcumin, a novel
p300/CREB-binding protein-specific inhibitor of acetyltransferase,
represses the acetylation of histone/nonhistone proteins and
histone acetyltransferase-dependent chromatin transcription. J Biol
Chem. 279:51163–51171. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kang J, Chen J, Shi Y, Jia J and Zhang Y:
Curcumin-induced histone hypoacetylation: The role of reactive
oxygen species. Biochem Pharmacol. 69:1205–1213. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kang SK, Cha SH and Jeon HG:
Curcumin-induced histone hypoacetylation enhances
caspase-3-dependent glioma cell death and neurogenesis of neural
progenitor cells. Stem Cells Dev. 15:165–174. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu Z, Xie Z, Jones W, Pavlovicz RE, Liu
S, Yu J, Li PK, Lin J, Fuchs JR, Marcucci G, et al: Curcumin is a
potent DNA hypomethylation agent. Bioorg Med Chem Lett. 19:706–709.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guo Y, Shan Q, Gong Y, Lin J, Shi F, Shi R
and Yang X: Curcumin induces apoptosis via simultaneously targeting
AKT/mTOR and RAF/MEK/ERK survival signaling pathways in human
leukemia THP-1 cells. Pharmazie. 69:229–233. 2014.PubMed/NCBI
|
|
24
|
Zhao G, Han X, Zheng S, Li Z, Sha Y, Ni J,
Sun Z, Qiao S and Song Z: Curcumin induces autophagy, inhibits
proliferation and invasion by downregulating AKT/mTOR signaling
pathway in human melanoma cells. Oncol Rep. 35:1065–1074. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Link A, Balaguer F, Shen Y, Lozano JJ,
Leung HC, Boland CR and Goel A: Curcumin modulates DNA methylation
in colorectal cancer cells. PLoS One. 8:e577092013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu P, Huang R, Xiong YL and Wu C:
Protective effects of curcumin against liver fibrosis through
modulating DNA methylation. Chin J Nat Med. 14:255–264.
2016.PubMed/NCBI
|
|
27
|
Agrawal DK and Mishra PK: Curcumin and its
analogues: Potential anticancer agents. Med Res Rev. 30:818–860.
2010.PubMed/NCBI
|
|
28
|
Naksuriya O, Okonogi S, Schiffelers RM and
Hennink WE: Curcumin nanoformulations: A review of pharmaceutical
properties and preclinical studies and clinical data related to
cancer treatment. Biomaterials. 35:3365–3383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Marquardt JU, Gomez-Quiroz L, Camacho
Arreguin LO, Pinna F, Lee YH, Kitade M, Dominguez MP, Castven D,
Breuhahn K, Conner EA, et al: Curcumin effectively inhibits
oncogenic NF-κB signaling and restrains stemness features in liver
cancer. J Hepatol. 63:661–669. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hu A, Huang JJ, Jin XJ, Li JP, Tang YJ,
Huang XF, Cui HJ, Xu WH and Sun GB: Curcumin suppresses
invasiveness and vasculogenic mimicry of squamous cell carcinoma of
the larynx through the inhibition of JAK-2/STAT-3 signaling
pathway. Am J Cancer Res. 5:278–288. 2014.PubMed/NCBI
|
|
31
|
Shu L, Khor TO, Lee JH, Boyanapalli SS,
Huang Y, Wu TY, Saw CL, Cheung KL and Kong AN: Epigenetic CpG
demethylation of the promoter and reactivation of the expression of
Neurog1 by curcumin in prostate LNCaP cells. AAPS J. 13:606–614.
2011. View Article : Google Scholar : PubMed/NCBI
|
